Nexavar Information

What's inside Nexavar

Nexavar in the News

Zacks Analyst Blog Highlights: Ambac, Onyx Pharmaceuticals, Pfizer ... - Trading Markets (press release)
The failure also cast shadow for Nexavar's long-term potential. Although worldwide Nexavar sales continued growth in 4Q07, US sales has been under great ...
Thu Mar 06 06:06:12 -0500 2008

Zacks Analyst Blog Highlights: Ambac, Onyx Pharmaceuticals, Pfizer ... - Centre Daily Times
Onyx Pharmaceuticals (Nasdaq: ONXX) lost one key near-term catalyst due to the early termination of its phase III ESCAPE trial of Nexavar for lung cancer on ...
Thu Mar 06 06:12:03 -0500 2008

Bayer Fourth-Quarter Net Falls on Year-Earlier Gain (Update1) - Bloomberg
Bayer shares fell 5.7 percent in Frankfurt trading last week after a study showed that Nexavar failed to help lung-cancer patients. ...
Thu Feb 28 02:40:05 -0500 2008

Nexavar Chemical Information

sorafenib - A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.